Last reviewed 2026-04-23 · How we verify

Conversion schedule - Week 3

This drug is a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain.

This drug is a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain. Used for Major depressive disorder, Generalized anxiety disorder.

At a glance

Mechanism of action

By blocking the reabsorption of serotonin, SSRIs like this drug allow more serotonin to be available in the synaptic cleft, which can help improve mood and reduce symptoms of depression and anxiety.

Approved indications

• Major depressive disorder
• Generalized anxiety disorder

Common side effects

• Nausea
• Headache
• Dizziness
• Insomnia
• Fatigue

Key clinical trials

• FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma (PHASE2)
• Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color） (PHASE2)
• Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study (PHASE4)
• Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies (PHASE2)
• A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations (PHASE3)
• Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants (PHASE3)
• Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants (PHASE3)
• Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.